New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer [Yahoo! Finance]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Yahoo! Finance
Data support company's plan to expand Decipher Prostate test to patients with metastatic disease SOUTH SAN FRANCISCO, Calif., September 15, 2024 BUSINESS WIRE Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial show that its Decipher Prostate Genomic Classifier is prognostic for clinical outcomes and predicts benefit from docetaxel in patients with metastatic prostate cancer. The findings were presented today ( Presentation #15960 ) at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona. These findings support Veracyte's plan to expand use of the Decipher Prostate test – currently widely used to guide care for localized prostate cancer – to patients with metastatic disease. Prostate cancer accounts for a fifth (approximately 375,000) of all male cancer-related deaths globally and the number is expected to double over the next two dec
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at Morgan Stanley from $26.00 to $28.00. They now have an "underweight" rating on the stock.MarketBeat
- Veracyte, Inc. (NASDAQ: VCYT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
- Veracyte, Inc. Just Recorded A 296% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]Yahoo! Finance
- Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at Scotiabank from $40.00 to $44.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Veracyte Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
VCYT
Earnings
- 11/6/24 - Beat
VCYT
Sec Filings
- 11/21/24 - Form 4
- 11/19/24 - Form 144
- 11/14/24 - Form 4
- VCYT's page on the SEC website